CLL/SLL Treatment Choices Based on Various Factors

Why It Matters

Understanding these drivers helps clinicians and payers address access barriers and tailor CLL/SLL therapy to patient‑specific risk and logistical realities, ultimately improving outcomes and resource allocation.

Key Takeaways

• Ven‑O chosen by 51% of first‑line CLL/SLL patients
• BTK inhibitors favored by 84% with del(17p)/TP53
• Patients >75 years prefer BTK inhibitors for convenience
• >100km distance increases BTK inhibitor use
• Only 64% documented multiple treatment options

Pulse Analysis

The therapeutic landscape for chronic lymphocytic leukemia and small lymphocytic lymphoma has shifted dramatically over the past decade, moving away from traditional chemoimmunotherapy toward targeted agents such as BTK inhibitors and the venetoclax‑obinutuzumab combination. These regimens offer deeper remissions and, in the case of venetoclax‑obinutuzumab, a finite treatment duration, which is attractive to patients and providers alike. However, the absence of robust head‑to‑head trials until recently forces clinicians to rely on real‑world evidence and individual patient characteristics when selecting first‑line therapy.

The Alberta cohort underscores how three key variables—genetic risk, age, and geographic proximity to infusion centers—drive treatment choice. Patients harboring del(17p) or TP53 mutations overwhelmingly opted for continuous BTK inhibition, reflecting confidence in the potency of these agents against high‑risk disease. Older patients and those residing more than 100 km from a center capable of delivering obinutuzumab favored BTK inhibitors, likely due to reduced travel burden and the convenience of oral administration. Notably, traditional clinical factors such as comorbidity scores or IGHV status showed no significant impact, suggesting that logistical considerations may outweigh some biological markers in everyday practice.

These findings have practical implications for both providers and health systems. The low rate of documented shared decision‑making points to an opportunity to improve patient engagement, ensuring that individuals are fully informed of all viable options. Payers and policymakers should consider supporting infrastructure that expands infusion capacity or subsidizes travel to mitigate geographic inequities. As newer head‑to‑head data emerge, clinicians will be better equipped to align treatment selection with both disease biology and patient lifestyle, fostering a more personalized and equitable CLL/SLL care paradigm.